Is metronidazole safe to use during pregnancy, and what is the recommended dosing regimen?

Metronidazole and Pregnancy

Metronidazole is safe to use during pregnancy, including the first trimester, and should be prescribed when clinically indicated for bacterial vaginosis or trichomoniasis. The evidence demonstrates no teratogenic risk, and the FDA classifies it as Pregnancy Category B 1.

Safety Profile

The FDA drug label confirms that metronidazole crosses the placental barrier but reproduction studies in rats at doses up to five times the human dose revealed no evidence of impaired fertility or harm to the fetus 1. Multiple studies and meta-analyses have not demonstrated a consistent association between metronidazole use during pregnancy and teratogenic or mutagenic effects in newborns 2.

Animal studies show no teratogenicity: No fetotoxicity was observed when metronidazole was administered orally to pregnant mice at doses approximately 1.5 times the most frequently recommended human dose 1. While some intrauterine deaths were observed in a single small study using intraperitoneal administration, the relationship to the drug remains unknown and this route is not clinically relevant 1.

Human data is reassuring: A prospective controlled cohort study of 228 women (86.2% with first-trimester exposure) found no difference in major malformation rates between metronidazole-exposed pregnancies (1.6%) and controls (1.4%) 3. A comprehensive literature review spanning nearly four decades confirms metronidazole is not teratogenic regardless of trimester 4.

Recommended Dosing Regimens in Pregnancy

For Bacterial Vaginosis

High-risk pregnant women (those with previous preterm delivery):

• Preferred regimen: Metronidazole 250 mg orally three times daily for 7 days 5
• Screen and treat at the earliest part of the second trimester 5
• Alternative: Metronidazole 2 g orally single dose OR clindamycin 300 mg orally twice daily for 7 days 5

Low-risk pregnant women (no previous preterm delivery) with symptomatic BV:

• Preferred regimen: Metronidazole 250 mg orally three times daily for 7 days 5
• Alternative: Metronidazole 2 g orally single dose OR clindamycin 300 mg orally twice daily for 7 days OR metronidazole gel 0.75%, one full applicator intravaginally twice daily for 5 days 5

The lower 250 mg dose (rather than the standard 500 mg used in non-pregnant women) is recommended to minimize fetal exposure while maintaining efficacy 5.

For Trichomoniasis

• Recommended regimen: Metronidazole 2 g orally in a single dose 5
• Alternative: Metronidazole 500 mg twice daily for 7 days 5

The FDA label states that use for trichomoniasis in the first trimester should be carefully evaluated, though it does not contraindicate it 1. More recent CDC guidelines (1998) removed the first-trimester contraindication that existed in earlier 1993 guidelines [5 vs 6].

Important Clinical Considerations

Evolution of Guidelines

Critical distinction: The 1993 CDC guidelines stated metronidazole was contraindicated in the first trimester 6. However, the 1998 CDC guidelines removed this contraindication and now recommend metronidazole throughout pregnancy when indicated 5. This reflects accumulating safety data.

Treatment Benefits vs. Risks

Bacterial vaginosis treatment in high-risk women may reduce preterm delivery 5, 2. Three of four randomized controlled trials showed that treating asymptomatic BV in women with previous preterm delivery reduced preterm birth 2.

However, for trichomoniasis, a paradoxical finding exists: One large randomized trial found that treating asymptomatic trichomoniasis in pregnancy actually increased preterm delivery (19.0% vs 10.7%, relative risk 1.8) 7. This was primarily due to increased spontaneous preterm labor. Therefore, routine screening and treatment of asymptomatic pregnant women for trichomoniasis cannot be recommended 7.

Potential Adverse Effects

One study noted a possible association with spontaneous abortion (70% increased risk), though this must be interpreted cautiously as the severity of genitourinary infection itself is a major confounder 8. A reduced neonatal birth weight was observed in one study, even among term infants, though without differences in prematurity rates 3.

Screening Recommendations

The U.S. Preventive Services Task Force recommends against screening for bacterial vaginosis in asymptomatic pregnant women at low risk for preterm delivery (Grade D recommendation) 9. For high-risk women, evidence is insufficient to assess the balance of benefits and harms (I statement) 9.

Practical Algorithm

For symptomatic infections:

1. Treat bacterial vaginosis or trichomoniasis with metronidazole at any trimester using recommended doses
2. Use lower doses in pregnancy (250 mg TID for BV) to minimize fetal exposure
3. Follow up at 1 month in high-risk women to ensure treatment success 5

For asymptomatic infections:

1. Screen high-risk women (previous preterm delivery) for BV in early second trimester
2. Treat if positive with metronidazole 250 mg TID for 7 days
3. Do NOT routinely screen or treat asymptomatic trichomoniasis in pregnancy
4. Do NOT screen low-risk asymptomatic women for BV

Common Pitfalls

• Outdated information: Many clinicians still believe metronidazole is contraindicated in the first trimester based on older guidelines. Current evidence supports its use throughout pregnancy 5, 2.
• Overtreating asymptomatic trichomoniasis: This may actually worsen outcomes and increase preterm delivery 7.
• Using clindamycin vaginal cream: This is NOT recommended in pregnancy as two randomized trials showed increased preterm deliveries 5.
• Underdosing: While lower doses are used in pregnancy for BV (250 mg vs 500 mg), ensure adequate duration (7 days) for optimal efficacy.